Uri Lopatin

Uri Lopatin, MD, is a serial biotech entrepreneur. He co-founded Assembly Pharmaceuticals as the Chief Medical Officer in 2012, and became Chief Medical Officer and Vice President of R&D for Assembly Bio (NASDAQ:ASMB) following the merger of Assembly Pharma with Ventrus Biosciences in 2014. As part of ASMB, he helped raise over $300 million to move their first two generations of novel therapeutics for hepatitis B into global phase 1 and phase 2 clinical studies.

Prior to that, he held clinical and translational science roles at Schering Plough, Roche, and Gilead Sciences, and was a Visiting Partner at Y Combinator. Uri is an infectious disease physician and has published and patented broadly in virology and immunology. He received his training in Internal Medicine at UMDNJ-New Jersey Medical School, University of Washington, NYU Medical Center and fellowship training in Infectious Disease at the National Institutes of Health.